Valeant Pharmaceuticals International Inc., which is finalizing a contract for a new chief executive, lately has contended with questions about its business and accounting practices. The drugmaker's 10-K annual report, which it is late in filing, could have new information about the company's past problems, and what's ahead. Here are five things to look for when the 10-K is filed.
